The World Medical Journal

first with the newest, about adding other insulins to the present ample market. Hopeless confusion can outweigh minor advantages of new products. Five standard insulins are now available in this country. Most of them are now familiar to practicing physicians and their patients. Those insulins and their combinations can do anything for any diabetic patient that is planned by informed physicians. Few disadvantages are inherent in them. In the various fields in which they are indicated they are fairly consistent, reliable and predictable in action and performance. Before new preparations are introduced, it should be clearly apparent that they possess decisive advantages over those now available. If that is determined to be a fact, it would be desirable to introduce the new insulins to substitute for and replace existing preparations. More need not be added. If those which they replace could be withdrawn from the market, with the simple assurance that the new preparations will do the same job better, and can be substituted directly in the management of individual diabetic patients, the new preparations could simplify rather than confuse the commercial insulin situation.